Skip to main content

Table 2 Differential methylation in non-small cell lung cancers (NSCLCs)

From: Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC)

 

AMP a (NSCLC)

AMP (Control)

P value b

log 10 (OR) (95% CI)

P value c

Sen d

Spe d

AUC d

AGTR1

12.88%

4.48%

1.06 × 10-7

3.49 (2.08, 4.91)

1.30 × 10-6

59.73%

79.59%

0.71

GALR1

18.31%

2.91%

6.58 × 10-9

2.56 (1.5, 3.63)

2.30 × 10-6

46.98%

85.03%

0.67

NTSR1

9.37%

0.56%

1.09 × 10-9

9.02 (5.48, 12.55)

5.90 × 10-7

44.30%

94.56%

0.70

SLC5A8

25.59%

11.66%

4.77 × 10-12

3.80 (2.51, 5.09)

7.80 × 10-9

52.35%

88.44%

0.67

ZMYND10

6.95%

12.82%

1.08 × 10-7

-4.61 (-6.27, -2.95)

5.20 × 10-8

73.15%

92.52%

0.80

LINE-1

72.10%

76.76%

2.39 × 10-12

-10.3 (-13.5, -7.2)

1.80 × 10-10

-

-

-

Referencee

1.78%

1.83%

2.85 × 10-1

-19.37 (-45.35, 6.62)

0.14

-

-

-

  1. aDifferential methylation analysis was conducted between 150 NSCLC and adjacent normal tissues. AMP represents average methylation percentage. b P valueb is the Bonferroni adjusted P value which is based on paired t-test comparing the intensity of the methylation signals between case and control. cThe log10(OR) and P valuec represent log-transformed odds ratio and P value based on logistic regression adjusted by sex, age and smoking status. dSensitivity, specificity and area under the curve (AUC) were calculated with a logistic regression prediction model without adjustment for sex, age and smoking status. eReference site was a C site that was not in the CpG site; therefore, no or a low-methylated signal would be detected and a nonsignificant association should be detected between cancer and normal tissues.